GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Intra Oral Kinetics of Fluoride Containing Dentifrices
Not Applicable
Completed
- Conditions
- Tooth Erosion
- Interventions
- Other: Comparator DentifriceOther: Test DentifriceOther: Reference DentifriceOther: Orange JuiceOther: De-ionised water
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT02548156
- Locations
- 🇬🇧
GSK Investigational Site, Ellesmere Port, Cheshire, United Kingdom
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.
Phase 1
Completed
- Conditions
- Respiratory Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT02547974
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
Phase 3
Completed
- Conditions
- Virus DiseasesRabies
- Interventions
- Biological: RabipurProcedure: Blood samplingBiological: Purified Chick-Embryo Cell Rabies Vaccine
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 459
- Registration Number
- NCT02545517
- Locations
- 🇨🇭
GSK Investigational Site, Zuerich, Switzerland
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
Phase 1
Completed
- Conditions
- Postpartum Hemorrhage
- Interventions
- Drug: IM oxytocin 10 IUDrug: IH oxytocin 50 mcgDrug: IH oxytocin 200 mcgDrug: IH oxytocin 400 mcgDrug: IH oxytocin 600 mcgDrug: Placebo
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02542813
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes in School Children
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Dietary Supplement: Fortified malt based food
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 924
- Registration Number
- NCT02542865
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Experimental Oral Rinse 1Device: Experimental Oral Rinse 2Other: Placebo Oral RinseDrug: Standard fluoride toothpaste
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT02542943
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
In Vivo Investigation of Initial Stages of Enamel Erosion
Not Applicable
Completed
- Conditions
- Tooth Erosion
- Interventions
- Other: Sodium fluoride + potassium nitrateOther: Potassium nitrate
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT02533466
- Locations
- 🇬🇧
GSK Investigational Site, Bristol, United Kingdom
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Phase 3
Terminated
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 161
- Registration Number
- NCT02531633
- Locations
- 🇬🇧
GSK Investigational Site, Reading, United Kingdom
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT02528357
- Locations
- 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT02522299
- Locations
- 🇩🇰
GSK Investigational Site, Odense, Denmark
© Copyright 2025. All Rights Reserved by MedPath